Product Images Lamivudine

This is a report on the effectiveness of Lamivudine for treating HIV-1. The dosages mentioned are 150mg twice daily and 300mg once daily. The goal of the treatment was to achieve and maintain HIV-1 RNA levels below 400 copies/mL. The effectiveness was measured using the Roche AMPLICOR HIV-1 MONITOR at different treatment times. The proportion of responders at each visit was reported for the study.*

NDC 69097-167-02 is a medicine for prescription use only. It contains Lamivudine USP at a concentration of 300mg per tablet. The package should be stored between 20°C to 25°C (68°F to 77°F). The manufacturer is Cipla Ltd. located in Verna, Goa, India. The medicine is intended for use only under medical supervision and should be kept out of the reach of children. The package contains 30 tablets that are controlled for temperature. The batch number, product GTIN, serial number, expiry, and lot number are provided in an area that will be overprinted during commercial packing.*

This is a description of a medicine with the NDC code 69097-166-03 which is available only by prescription. It is in tablet form and each tablet contains 150mg of Lamivudine, USP. The recommended dosage information is available in the accompanying prescribing information. The tablets should be stored within a temperature range of 20°C to 25°C (68°F to 77°F) and kept away from children's reach. They are manufactured in India by Cipla Ltd. for Cipla USA, Inc. The packaging consists of 60 tablets and has a GTIN, S/N, EXP, and Lot number for batch overprinting during commercial packing.*